Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Researchers study new drug and indications for heated chemotherapy treatment

Studies have shown that surgery combined with Intraperitoneal Hyperthermic Chemotherapy (IPHC) can improve survival rates for select patients with peritoneal carcinoma (cancer of the lining of the abdominal cavity) that has spread from colorectal or appendix cancer.

17 Mar 2008

Good news for people with glycogen storage disease type Ia

A gene therapy treatment that restores a missing liver enzyme in test animals could provide a cure for a rare metabolic disorder in humans, according to Duke University Medical Center researchers.

13 Mar 2008

Combined therapeutic approach of stenting and photodynamic therapy improves survival in late stage liver cancer patients

A combined therapeutic approach of stenting and photodynamic therapy may improve survival rates for patients suffering from advanced liver bile duct cancer, according to a study published this month in Clinical Gastroenterology and Hepatology , the official journal of the American Gastroenterological Association (AGA) Institute.

12 Mar 2008

Discovery of family of genes linked to the development of liver cancer

An interdisciplinary team of researchers at Stony Brook University Medical Center has identified a family of genes linked to the development of liver cancer.

28 Feb 2008

ImClone Systems enrols first patient in clinical trial of IMC-1121B to treat liver cancer

ImClone Systems Incorporated has announced that it has enrolled the first patient in a disease-directed Phase II clinical trial of IMC-1121B to treat patients with advanced hepatocellular carcinoma (liver cancer).

26 Feb 2008

New Jefferson trial to test radiation-emitting beads against advanced liver cancer

Liver cancer specialists at Jefferson's Kimmel Cancer Center in Philadelphia are beginning an 18-month study of a new treatment for liver cancer.

13 Feb 2008

Mayo Clinic Proceedings contributors discuss impact of donor organ allocation system

Liver transplant is a life saving treatment option for people with end-stage liver disease.

7 Feb 2008

microRNAs may help predict survival in liver cancer

Tiny molecules that help cells regulate which proteins they make might one day help doctors predict which liver-cancer patients are likely to live longer than others, new research suggests.

4 Feb 2008

Kidney cancer drug attacks a major type of acute myeloid leukemia

A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia (AML), the most common and lethal form of adult leukemia, researchers at The University of Texas M. D. Anderson Cancer Center report in the Jan. 29 edition of the Journal of the National Cancer Institute.

30 Jan 2008

Untreated blood disorder leads to liver cancer and arthritis

Australian researchers have discovered that more than one quarter of men with hemochromatosis develop liver cancer, arthritis and other complications.

20 Jan 2008

Acanthus ilicifolius plant may combat liver cancer

Liver cancer is the fifth most common cancer in the world with a poor prognosis. About three quarters of the cases of liver cancer are found in Southeast Asia, including China, Hong Kong, Taiwan, Korea, India, and Japan.

17 Jan 2008

Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer

As the incidence of liver cancer continues to grow - fueled in large part, by rising rates of hepatitis C infections - so too does the need for tests to help diagnose the disease at an earlier stage.

16 Jan 2008

Gender differences in liver cancer

A fundamental difference in the way males and females respond to chronic liver disease at the genetic level helps explain why men are more prone to liver cancer, according to MIT researchers.

16 Jan 2008

New biomarker for predicting liver cancer spread and survival discovered

New research has shown that a unique pattern of microRNAs, small RNA molecules that regulate gene activity, can accurately predict whether liver cancer will spread and whether liver cancer patients will have shorter or longer survival, even patients with early stage disease.

7 Jan 2008

Gene variation increases risk of liver tumor in patients with cirrhosis

A particular gene variation appears to significantly increase the risk that individuals with cirrhosis of the liver will go on to develop hepatocellular carcinoma (HCC), a liver tumor that is the third leading cause of cancer death.

2 Jan 2008

Drug effective for hepatitis C patients with low platelets

For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease.

2 Jan 2008

Optimal therapy for U.S. hepatitis C patients

As reported recently in the journal Hepatology, WIN-R, a multicenter study of over 5,000 patients with hepatitis C virus (HCV) showed treatment with weight-based REBETOL ribavirin, USP) (RBV) in combination with pegylated interferon (PEG-IFN) alfa-2b achieved significantly higher rates of sustained virologic response (SVR) and lower relapse rates compared to combination therapy using a flat dose of RBV 800 mg/day. Superior response was found particularly in patients with the most difficult-to-treat form of the disease, genotype 1 HCV. Efficacy was consistent across all weight groups.

28 Dec 2007